Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma

详细信息    查看全文

• 作者：Junlin Yi (1)
  Xiaodong Huang (1)
  Li Gao (1)
  Jingwei Luo (1)
  Shiping Zhang (1)
  Kai Wang (1)
  Yuan Qu (1)
  Jianping Xiao (1)
  Guozhen Xu (1)
  
• 关键词：Locally advanced ; Nasopharyngeal carcinoma ; Concurrent chemoradiotherapy ; Intensity ; modulated radiotherapy with simultaneous integrated boost
• 刊名：Radiation Oncology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：9
• 期：1
• 全文大小：217 KB
• 参考文献：1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. / J Clin Oncol 1998, 16:1310-317.
  2. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, Leung SF, Thephamongkhol K, Pignon JP: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. / Int J Radiat Oncol Biol Phys 2006, 64:47-6. CrossRef
  3. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. / J Clin Oncol 2002, 20:2038-044. CrossRef
  4. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, Wu PM, Law MW, Kwok CC, Yau CC, Wan KY, Chan RT, Choy DD: Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. / J Clin Oncol 2004, 22:2643-653. CrossRef
  5. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. / J Clin Oncol 2003, 21:631-37. CrossRef
  6. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HS, Lee KS, Loong S, Sethi V, Chua EJ, Machin D: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. / J Clin Oncol 2005, 23:6730-738. CrossRef
  7. Chau RM, Teo PM, Kam MK, Leung SF, Cheung KY, Chan AT: Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord. / Med Dosim 2007, 32:263-70. CrossRef
  8. Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ: Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. / Int J Radiat Oncol Biol Phys 2000, 48:329-37. CrossRef
  9. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. / J Clin Oncol 2009, 27:3684-690. CrossRef
  10. Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G: A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. / Radiother Oncol 2012, 104:286-93. CrossRef
  11. Wang TJC, Riaz N, Cheng SK, Lu JJ, Lee NY: Intensity-modulated radiation therapy for nasopharyngeal carcinoma: a review. / J Radiat Oncol 2012, 1:129-46. CrossRef
  12. Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, Wu SX: Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. / J Clin Oncol 2005, 23:8461-468. CrossRef
  13. Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, Guo Y, Huang YJ, Guan ZZ: The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. / BMC Cancer 2010, 10:558. CrossRef
  14. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J: Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. / Lancet Oncol 2012, 13:163-71. CrossRef
  15. Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, Tan T, Chua DT, O'Sullivan B, Tung R, Ng WT, Leung TW, Leung SF, Yau S, Zhao C, Tan EH, Au GK, Siu L, Fung KK, Lau WH: A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. / Radiother Oncol 2011, 98:15-2. CrossRef
  16. Lee AW, Tung SY, Chua DT, Ngan RK, Chappell R, Tung R, Siu L, Ng WT, Sze WK, Au GK, Law SC, O'Sullivan B, Yau TK, Leung TW, Au JS, Sze WM, Choi CW, Fung KK, Lau JT, Lau WH: Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. / J Natl Cancer Inst 2010, 102:1188-198. CrossRef
  17. Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, Siu L, Tan T, Chan LK, Ng WT, Leung TW, Fu YT, Au GK, Zhao C, O'Sullivan B, Tan EH, Lau WH: Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. / Eur J Cancer 2011, 47:656-66. CrossRef
  18. Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P: Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: a review. / Crit Rev Oncol Hematol 2010, 73:111-25. CrossRef
  19. Kwong DL, Sham JS, Leung LH, Cheng AC, Ng WM, Kwong PW, Lui WM, Yau CC, Wu PM, Wei W, Au G: Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. / Int J Radiat Oncol Biol Phys 2006, 64:374-81. CrossRef
  20. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ, Zhao C: Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. / Cancer 2011, 117:1874-883. CrossRef
  21. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, Kwong DL, Lau WH: Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. / Int J Radiat Oncol Biol Phys 2005, 61:1107-116. CrossRef
  22. Yeh SA, Tang Y, Lui CC, Huang YJ, Huang EY: Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. / Int J Radiat Oncol Biol Phys 2005, 62:672-79. CrossRef
  23. Yi JL, Gao L, Huang XD, Li SY, Luo JW, Cai WM, Xiao JP, Xu GZ: Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institution. / Int J Radiat Oncol Biol Phys 2006, 65:161-68. CrossRef
  24. Lin S, Lu JJ, Han L, Chen Q, Pan J: Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. / BMC Cancer 2010, 10:39. CrossRef
  25. Wang R, Wu F, Lu H, Wei B, Feng G, Li G, Liu M, Yan H, Zhu J, Zhang Y, Hu K: Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study. / J Cancer Res Clin Oncol 2013, 139:139-45. CrossRef
  26. Su SF, Han F, Zhao C, Huang Y, Chen CY, Xiao WW, Li JX, Lu TX: Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. / Chin J Cancer 2011, 30:565-73. CrossRef
  27. Bentzen SM: Radiobiological considerations in the design of clinical trials. / Radiother Oncol 1994, 32:1-1. CrossRef
  28. Sze WM, Lee AW, Yau TK, Yeung RM, Lau KY, Leung SK, Hung AW, Lee MC, Chappell R, Chan K: Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. / Int J Radiat Oncol Biol Phys 2004, 59:21-7. CrossRef
  29. Teo PM, Leung SF, Tung SY, Zee B, Sham JS, Lee AW, Lau WH, Kwan WH, Leung TW, Chua D, Sze WM, Au JS, Yu KH, Of SK, Kwong D, Yau TK, Law SC, Sze WK, Au G, Chan AT: Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). / Radiother Oncol 2006, 79:27-3. CrossRef
  30. Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC: Another way to estimate outcome of advanced nasopharyngeal carcinoma–is concurrent chemoradiotherapy adequate? / Int J Radiat Oncol Biol Phys 2004, 60:156-64. CrossRef
  31. Espeli V, Zucca E, Ghielmini M, Giannini O, Salatino A, Martucci F, Richetti A: Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. / Oral Oncol 2012, 48:266-71. CrossRef
  32. Ho KF, Swindell R, Brammer CV: Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: a retrospective comparison from New Cross Hospital, Wolverhampton, UK. / Acta Oncol 2008, 47:1513-518. CrossRef
  33. Kim TH, Ko YH, Lee MA, Kim BS, Chung SR, Yoo IR, Jung CK, Kim YS, Kim MS, Sun DI, Hong YS, Lee KS, Kang JH: Treatment outcome of cisplatin-based concurrent chemoradiotherapy in the patients with locally advanced nasopharyngeal cancer. / Cancer Res Treat 2008, 40:62-0. CrossRef
  
• 作者单位：Junlin Yi (1)
  Xiaodong Huang (1)
  Li Gao (1)
  Jingwei Luo (1)
  Shiping Zhang (1)
  Kai Wang (1)
  Yuan Qu (1)
  Jianping Xiao (1)
  Guozhen Xu (1)
  
  1. Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, NO 17, Panjiayuan nanli, Chaoyang District, Beijing, 100021, China
  
• ISSN：1748-717X

文摘

Objective To compare the treatment outcomes of intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) alone to concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal carcinoma (NPC). Methods From November 2001 to December 2009, 333 patients with pathologically diagnosed, locoregionally advanced NPC were treated by IMRT-SIB with or without weekly cisplatin concurrent chemotherapy at our institute. Among them, 62 patients received neo- or adjuvant chemotherapy or molecular target drugs were excluded from this analysis. There were 129 patients received IMRT-SIB alone, and 142 patients received IMRT-SIB with weekly cisplatin 30?mg/m2 for 7?weeks. The radiotherapy protocol was identical for each group. Results There were no significant differences in survival between CCRT and IMRT-SIB group in terms of gender, T/N classifications and concurrent chemoradiotherapy. The 5-year local control (LC), overall survival (OS), disease-free survival (DFS) and distant metastasis-free survival (DMFS) for the entire group were 87.0%, 79.4%, 69.7 and 83.3%, respectively. The LC, OS, DFS and DMFS for CCRT and IMRT-SIB alone groups were 80.6% vs. 90.8% (P--.10), 71.7% vs. 83.2% (P--.201), 63.9% vs. 74.6% (P--.07), and 79.6% vs. 86.0% (P--.27), respectively. Conclusion Compared to CCRT, IMRT-SIB alone had demonstrated similar disease LC, OS, DFS and DMFS in locoregionally advanced NPC. Careful radiation target volume design and simultaneous integrated boost may play a role that overrides the benefit from concurrent chemotherapy. Further investigation with randomized study is necessary to determine whether IMRT-SIB alone can achieve similar outcomes of concurrent chemoradiotherapy.